Side-by-side comparison of AI visibility scores, market position, and capabilities
British consumer health company with £14B revenue; Lysol, Mucinex, Nurofen, and Durex brands managing Mead Johnson infant formula litigation while competing with P&G and J&J.
Reckitt is a British multinational consumer health and hygiene company producing market-leading brands including Nurofen (ibuprofen), Strepsils, Dettol, Lysol, Durex, Mucinex, Enfamil infant formula, and Woolite — competing across OTC health, hygiene and home, and nutrition categories. Listed on the London Stock Exchange (LSE: RKT) and headquartered in Slough, England, Reckitt generates approximately £14 billion ($17 billion) in annual revenue. The company has undergone significant portfolio reshaping, divesting its Infant Formula & Child Nutrition (IFCN) business in some markets and selling Mead Johnson Nutrition operations.\n\nReckitt's business is organized into two segments: Health (Nurofen, Strepsils, Gaviscon, Mucinex, DayQuil/NyQuil in North America) and Hygiene and Home (Lysol/Dettol disinfectants, Finish dishwasher tablets, Vanish stain remover, Air Wick). The Health segment benefits from strong brand equity in OTC medications that command premium pricing. The Hygiene segment's Lysol brand benefited significantly from COVID-19 disinfectant demand and has sustained elevated brand awareness post-pandemic.\n\nIn 2025, Reckitt faces ongoing challenges from its $2.4 billion acquisition of Mead Johnson (Enfamil) — the company has faced significant litigation related to NEC (necrotizing enterocolitis) lawsuits claiming preterm infant formula contributed to infant deaths, resulting in large court judgments against Reckitt in 2024. The company is managing these legal liabilities while continuing to run its core consumer health and hygiene portfolio. Reckitt competes with Procter & Gamble, Johnson & Johnson, and Haleon for OTC health and hygiene market share. The 2025 strategy focuses on its Power Brands in health and hygiene, cost efficiency, and resolving the Mead Johnson litigation exposure.
$3.5M annual revenue 2025; $86.1M total funding (Series C Oct 2023); deployed in 60+ countries; acquired Regen adding 130K acres; 134 employees; precision agriculture market $8.7B 2024; subscription-based model
CropX was founded in 2014 in Tel Aviv, Israel, with the mission of helping farmers improve crop yields and reduce resource consumption through precision agriculture technology. The company developed soil sensing hardware and analytics software that translate subsurface soil data into actionable irrigation and nutrient management recommendations, enabling farms of any size to optimize inputs based on actual field conditions rather than generalized agronomic guidelines.\n\nCropX's platform combines wireless soil sensors that measure moisture, temperature, and electrical conductivity at multiple depths with a cloud-based analytics engine that integrates weather data, satellite imagery, and farm management records. Recommendations are delivered via a mobile app, enabling farm managers to make data-driven irrigation decisions in real time. The 2023 acquisition of Regen added 130,000 acres of managed farmland to its platform and expanded its capabilities in carbon and regenerative agriculture. CropX is deployed in 60+ countries across a diverse range of crops and farm types.\n\nCropX has raised $86.1M in total funding, including a Series C in October 2023, and has grown to serve 20,000+ customers with a team of 134 employees. The company's international deployment footprint — spanning North America, Europe, Australia, and emerging agricultural markets — reflects the universal applicability of data-driven soil management. CropX sits at the intersection of precision agriculture, water conservation, and sustainable farming, three of the highest-priority investment themes in global food systems.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.